XML 50 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 3 Months Ended
Mar. 31, 2016
USD ($)
Feb. 26, 2015
USD ($)
Mar. 31, 2017
USD ($)
Item
Mar. 31, 2016
USD ($)
License And Collaboration Agreements [Line Items]        
Licensing revenue     $ 293,000 $ 236,000
Deferred revenue     $ 14,800,000  
Eddingpharm        
License And Collaboration Agreements [Line Items]        
Non-refundable up-front received   $ 15,000,000    
Licensing agreement term   16 years    
Number of indications of the regulatory milestone events relating to the submission and approval | Item     3  
Amounts to be received upon achievement of the regulatory milestone events     $ 33,000,000  
Sales-based milestone event payment     120,000,000  
Eddingpharm | Maximum        
License And Collaboration Agreements [Line Items]        
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone     153,000,000  
Amounts to be received upon achievement of the regulatory milestone events     15,000,000  
Sales-based milestone event payment     50,000,000  
Eddingpharm | Minimum        
License And Collaboration Agreements [Line Items]        
Amounts to be received upon achievement of the regulatory milestone events     1,000,000  
Sales-based milestone event payment     $ 5,000,000  
Eddingpharm | Clinical Trial Application        
License And Collaboration Agreements [Line Items]        
Licensing agreement term 4 years      
Non-refundable milestone payment $ 1,000,000      
Biologix FZCo        
License And Collaboration Agreements [Line Items]        
Revenue recognition period of non-refundable up-front payment 10 years